{"disease":{"id":"stage-iii-nasopharyngeal-carcinoma","name":"stage iii nasopharyngeal carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03010150","title":"Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":471,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00274937","title":"Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06532279","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06682442","title":"Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06064097","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02538510","title":"Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT00408694","title":"Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02339558","title":"Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06980038","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04870840","title":"Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02388932","title":"Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT04231864","title":"Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Alain Algazi","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}